RT Journal Article
SR Electronic
T1 Omalizumab: Where does it fit into current asthma management?
JF Cleveland Clinic Journal of Medicine
JO Cleve Clin J Med
FD Cleveland Clinic
SP 251
OP 261
VO 71
IS 3
A1 Rambasek, Todd E.
A1 Lang, David M.
A1 Kavuru, Mani S.
YR 2004
UL http://www.ccjm.org/content/71/3/251.abstract
AB Omalizumab (Xolair), a monoclonal antibody, is a new agent that blocks the allergic cascade at its primary step. This drug offers substantial promise for patients with moderate-to-severe, persistent allergic asthma that is not well controlled. But due to the cost of the drug, limitations on dosage, and available clinical trial data, it is not a first-line therapy. This review discusses how this drug works, which patients will be candidates for it, and the practical aspects of using it.